How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring egfr gene-sensitive mutations?

Journal of Thoracic Oncology

Volumn 8, Issue 1, 2013, Pages 89-95

  Hata, Akito ^a   Katakami, Nobuyuki ^a   Yoshioka, Hiroshige ^b   Kunimasa, Kei ^b   Fujita, Shiro ^a   Kaji, Reiko ^a   Notohara, Kenji ^b   Imai, Yukihiro ^c   Tachikawa, Ryo ^c   Tomii, Keisuke ^c   Korogi, Yohei ^b   Iwasaku, Masahiro ^b   Nishiyama, Akihiro ^b   Ishida, Tadashi ^b  

^a INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^b KURASHIKI CENTRAL HOSPITAL   (Japan)

^c KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

Author keywords

EGFR mutation; Epidermal growth factor receptor tyrosine kinase inhibitor; Squamous cell carcinoma

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; NUCLEIC ACID; THYROID TRANSCRIPTION FACTOR 1;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; DRUG EFFICACY; EXON; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SMOKING; TREATMENT OUTCOME;

EID: 84871950516     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31827690b5     Document Type: Article

References (44)

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to geftinib. N Engl J Med 2004;350:2129-2139.
2. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to geftinib therapy. Science 2004;304:1497-1500.
3. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346.
4. Nagai Y, Miyazawa H, Huqun, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005;65: 7276-7282.
5. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
6. Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 2011;24:1348-1359.
7. Pelosi G, Rossi G, Bianchi F, et al. Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profling and eventual diagnoses on surgical specimens. J Thorac Oncol 2011;6:1039-1049.
8. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription fac-tor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol 2010;41:20-25.
9. Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Lab Med 2008;132:384-396.
10. Reis-Filho JS, Simpson PT, Martins A, Preto A, Gärtner F, Schmitt FC. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch 2003;443:122-132.
11. Chu PG, Lyda MH, Weiss LM. Cytokeratin 14 expression in epithelial neoplasms: a survey of 435 cases with emphasis on its value in differentiating squamous cell carcinomas from other epithelial tumours. Histopatholog y 2001;39:9-16.
12. Yanagita E, Imagawa N, Ohbayashi C, Itoh T. Rapid multiplex immuno-histochemistry using the 4-antibody cocktail YANA-4 in differentiating primary adenocarcinoma from squamous cell carcinoma of the lung. Appl Immunohistochem Mol Morphol 2011;19:509-513.
13. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23:857-865.
14. Sugio K, Uramoto H, Ono K, et al. Mutations within the tyrosine kinase domain of EGFR gene specifcally occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 2006;94:896-903.
15. Tanaka T, Matsuoka M, Sutani A, et al. Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer 2010;126:651-655.
16. Bai H, Mao L, Wang HS, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009;27:2653-2659.
17. Lee SY, Kim MJ, Jin G, et al. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol 2010;5:1734-1740.
18. Miyamae Y, Shimizu K, Hirato J, et al. Signifcance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. Oncol Rep 2011;25:921-928.
19. Vachtenheim J, Horáková I, Novotná H, Opáalka P, Roubková H. Mutations of K-ras oncogene and absence of H-ras mutations in squa-mous cell carcinomas of the lung. Clin Cancer Res 1995;1:359-365.
20. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007;98:1817-1824.
21. Marchetti A, Felicioni L, Buttitta F. Assessing EGFR mutations. N Engl J Med 2006;354:526-8; author reply 526.
22. Shukuya T, Takahashi T, Kaira R, et al. Effcacy of geftinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci 2011;102:1032-1037.
23. Morita S, Okamoto I, Kobayashi K, et al. Combined survival analysis of prospective clinical trials of geftinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2009;15:4493-4498.
24. Mok TS, Wu YL, Thongprasert S, et al. Geftinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
25. Mitsudomi T, Morita S, Yatabe Y, et al.; West Japan Oncology Group. Geftinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
26. Maemondo M, Inoue A, Kobayashi K, et al.; North-East Japan Study Group. Geftinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.
27. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as frst-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-742.
28. Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verifed squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 2012;18:1167-1176.
29. Travis WD, Rekhtman N, Riley GJ, et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol 2010;5:411-414.
30. Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology & Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004.
31. Kang SM, Kang HJ, Shin JH, et al. Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcino-matous components of adenosquamous carcinoma of the lung. Cancer 2007;109:581-587.
32. Ohtsuka K, Ohnishi H, Fujiwara M, et al. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosqua-mous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component. Cancer 2007;109:741-750.
33. Toyooka S, Yatabe Y, Tokumo M, et al. Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung. Int J Cancer 2006;118:1588-1590.
34. Tochigi N, Dacic S, Nikiforova M, Cieply KM, Yousem SA. Adenosquamous carcinoma of the lung: a microdissection study of KRAS and EGFR mutational and amplifcation status in a western patient population. Am J Clin Pathol 2011;135:783-789.
35. Jia XL, Chen G. EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung. Lung Cancer 2011;74:396-400.
36. Sasaki H, Endo K, Yukiue H, Kobayashi Y, Yano M, Fujii Y. Mutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lung. Lung Cancer 2007;55:129-130.
37. Shiao TH, Chang YL, Yu CJ, et al. Epidermal growth factor receptor mutations in small cell lung cancer: a brief report. J Thorac Oncol 2011;6:195-198.
38. Tatematsu A, Shimizu J, Murakami Y, et al. Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res 2008;14:6092-6096.
39. Fukui T, Tsuta K, Furuta K, et al. Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. Cancer Sci 2007;98:1714-1719.
40. Zakowski MF, Ladanyi M, Kris MG; Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome Group. EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 2006;355:213-215.
41. Rekhtman N, Marchetti A, Lau C, et al. Analysis of EGFR and KRAS mutations in small cell carcinoma and large cell neuroendocrine carcinoma of lung. J Thor Oncol 2011;6 (Supplement 2):S346.
42. Roggli VL, Vollmer RT, Greenberg SD, McGavran MH, Spjut HJ, Yesner R. Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases. Hum Pathol 1985;16:569-579.
43. Sandler AB, Schiller JH, Gray R, et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in frst-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 2009;27:1405-1412.
44. Scagliotti G, Brodowicz T, Shepherd FA, et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 2011;6:64-70.